Who is sponsoring NCT01210183?

NCT01210183 is sponsored by Universidad Nacional de Rosario.

What drugs are being tested in NCT01210183?

Interventions in NCT01210183: Dextrose intraarticularly administered.

What condition does NCT01210183 study?

NCT01210183 studies Knee Osteoarthritis.

Is NCT01210183 still recruiting?

NCT01210183 is currently completed. Last updated 19 May 2014.

Last reviewed 2014-05-19 · How we verify

NCT01210183

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose Injections Without Weight Bearing Restriction: A Double Arthroscopic Assessment

Completed Phase 2/Phase 3 Last updated 19 May 2014

What this trial tests

Phase 2/Phase 3 trial testing Dextrose intraarticularly administered in Knee Osteoarthritis in 6 participants. Completed in 1 December 2013.

Timeline

1 July 2010

Primary endpoint
1 December 2013

1 December 2013

Quick facts

Lead sponsor	Universidad Nacional de Rosario
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	6
Start date	1 July 2010
Primary completion	1 December 2013
Estimated completion	1 December 2013
Sites	1 location across Argentina

Drugs / interventions tested

Dextrose intraarticularly administered — full drug profile →

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

Universidad Nacional de Rosario — full company profile →

Who can join

40 and older, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Quality of cartilage growth
Time frame: 0 to 3 months
A Jamshidi needle biopsy will be obtained at 45 degrees in the area of maximum cartilage growth and analyzed for quality/type of cartilage if such growth is seen.
Number of sections of medial condyle with loss, no change or growth of cartilage.
Time frame: 7.5 month mean
Arthroscopy of all 9 sections of the medial condyle for each of 6 knees will be viewed by each of 3 arthroscopers who will render their opinion for each section. They will compare sections from 1st and 2nd arthroscopy side by side, and will be asked to indicate loss of cartilage no change or growth of cartilage for each of sections on each of 6 knees. Still photos of the biopsy study site wiThe p

Sponsor's own description

Dextrose injection in end-stage knee arthritis will cause growth of cartilage cells in a particular area of complete cartilage loss. Dextrose concentration will be 12.5%. Cartilage status will be monitored by pre and post treatment arthroscopy views with specialized (methylene blue) staining for cartilage.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs.
Chen Y, Sun H, Yao X, Yu Y, et al · · 2021 · cited 9× · PMID 34783870 · DOI 10.1007/s00018-021-03983-8

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other Universidad Nacional de Rosario trials

Trials by the same sponsor.

NCT03498742 — Asthmatic Subjects Could Live Without Short Acting beta2 Agonists · completed
NCT03216941 — Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01210183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Nacional de Rosario
Last refreshed: 19 May 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01210183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing